Navigation Links
German Alliance for Industrial Biotechnology Debuts in Montreal
Date:7/13/2009

BERLIN, July 13 /PRNewswire/ -- The new "German Alliance for Industrial Biotechnology" is making its first appearance. An initiative recently launched by Germany Trade & Invest, the network includes both research institutions and producers, namely industrial biotechnology clusters and chemical parks, in addition to regional investment agencies. The alliance aims to bolster Germany's biotechnology sector by creating new business opportunities across the entire value chain. Members of the alliance will be presenting together at the Sixth Annual World Congress on Industrial Biotechnology and Bioprocessing from July 19-22 in Montreal, Canada.

Germany's biotechnology industry is the largest in Europe, posting annual revenues of over EUR 2 billion. There are nearly 600 biotechnology companies located in Germany. Within this industry, the industrial biotechnology sector has shown rapid growth in recent years. From 2005 to 2007, the industry doubled its revenue to EUR 50.4 million.

The "German Alliance for Industrial Biotechnology" brings together a number of partners. The network is made up of chemical parks, biotechnology start-ups, and scientific institutes from across Germany. Together, they initiate research and development projects that strengthen both academic and market competitiveness. A number of economic development agencies also contribute to the network, offering business services for investors and local expertise.

Rolf O. Gohdes, Director of Chemicals and Healthcare at Germany Trade & Invest, stated: "We believe the German Alliance for Industrial Biotechnology represents an exceptional chance for biotechnology companies to grow and prosper. Germany offers a number of unique business advantages. Our highly-skilled researchers and cutting-edge innovation combine to make Germany one of the most attractive locations for biotechnology in the world. Especially interesting are the chemical parks, which are setting the curve for others worldwide."

Germany's chemical parks provide a distinct business model for biotechnology companies. With the necessary infrastructure in place, this model creates a "plug and play" environment for companies, who can access all the necessary raw materials and supplies, find potential suppliers and research partners on site, and benefit from cost sharing.

Dr. Ralf Grote, Senior Manager of the German Cluster "Biocatalysis2021," will be discussing the potential of the German clusters of industrial biotechnology at this year's congress. In addition, Manfred Kircher, Chairman of the Board of Cluster Industrial Biotechnology 2021 e.V. (CLIB2021) will present international business solutions based on industrial biotechnology. Dr. Markus Wolperdinger, Director of Industrial Biotechnology at InfraLeuna GmbH, will highlight biorefinery as a case study, specifically the integration of bio-based processes and renewable resources into an established fossil-based refinery site.

Germany Trade & Invest will have representatives on hand at stand number 1101 in the exhibition hall of this year's congress in Montreal.

Germany Trade & Invest is the foreign trade and inward investment promotion agency of the Federal Republic of Germany. The organization advises foreign companies looking to expand their business activities in the German market. It provides information on foreign trade to German companies that seek to enter foreign markets.

    Eva Henkel
    eva.henkel@gtai.com
    Phone: +49-(0)30-200099-173
    Fax:   +49-(0)30-200099-111


'/>"/>
SOURCE Germany Trade and Invest
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine
2. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria
3. Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker
4. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
5. Life Science Alley: R&D Makes German Medical Technologies Top in Europe
6. CPA Acquires Renowned German Patent Research Specialist, SVPG
7. Stallergenes : Sublingual Desensitisation Tablets Oralair Grasses Approved in Germany
8. BIO 2008: Germany on Cutting Edge in Biomanufacturing
9. Pharmaxis Aridol Authorised for Sale in Germany
10. World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment
11. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... NC (PRWEB) , ... January 16, 2017 , ... ... company, received the prestigious Tibbetts Award from the U.S. Small Business Administration. ... “that have created a significant economic or social impact […] and are considered the ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks the ... evaluates the patent estate of a company, its impact and significance, and the likelihood ... the way in technologies that transform energy sources such as low dose X-ray and ...
(Date:1/12/2017)... 12, 2017   Protein Sciences Corporation , ... Flublok Influenza Vaccine ®, announced today that ... good safety results and induced strong neutralizing antibodies ... product is expected to advance into human clinical ... the Institute of Technology in Immunobiologicals of the ...
Breaking Biology Technology:
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):